This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

The Safety and Efficacy of Chorionic Villus Sampling for Early Prenatal Diagnosis of Cytogenetic Abnormalities

List of authors.
  • George G. Rhoads, M.D.,
  • Laird G. Jackson, M.D.,
  • Sarah E. Schlesselman, Ph.D.,
  • Felix F. de la Cruz, M.D.,
  • Robert J. Desnick, M.D.,
  • Mitchell S. Golbus, M.D.,
  • David H. Ledbetter, Ph.D.,
  • Herbert A. Lubs, M.D.,
  • Maurice J. Mahoney, M.D.,
  • Eugene Pergament, M.D.,
  • Joe Leigh Simpson, M.D.,
  • Robert J. Carpenter, M.D.,
  • Sherman Elias, M.D.,
  • Norman A. Ginsberg, M.D.,
  • James D. Goldberg, M.D.,
  • John C. Hobbins, M.D.,
  • Lauren Lynch, M.D.,
  • Patricia H. Shiono, Ph.D.,
  • Ronald J. Wapner, M.D.,
  • and Julia M. Zachary

Abstract

Chorionic villus sampling is a method of prenatal diagnosis in the first trimester of pregnancy in which tissue for genetic study is aspirated from the developing placenta by means of a catheter inserted transcervically under the guidance of ultrasonography. In this seven-center study, we compared the safety and efficacy of chorionic villus sampling in 2278 women with those of amniocentesis at 16 weeks' gestation in 671 women. Both groups were made up primarily of well-educated private patients; they were recruited in the first trimester of pregnancy and had viable pregnancies verified by ultrasound examination.

Cytogenetic diagnoses resulted from 97.8 percent of the chorionic villus sampling procedures and 99.4 percent of the amniocenteses (P<0.05); aneuploidy was found in 1.8 and 1.4 percent, respectively, of the cases in which diagnoses were made. Of the women who underwent chorionic villus sampling, 17 (0.8 percent) subsequently had an amniocentesis because the diagnosis was ambiguous. Two of the diagnoses of aneuploidy (one tetraploidy, one trisomy 22) were later proved to be incorrect. On the basis of pediatric examination of the infants subsequently born to the women in the sample, there were no errors in the determination of sex or the identification of the major trisomies (21, 18, and 13).

The rate of combined losses due to spontaneous and missed abortions, termination of abnormal pregnancies, stillbirths, and neonatal deaths was 7.2 percent in the group that underwent chorionic villus sampling and 5.7 percent in the group that had amniocentesis. After adjustment for slight differences in gestational and maternal age, the total loss rate for the women in the chorionic villus sampling group exceeded that for the amniocentesis group by only 0.8 percentage points (80 percent confidence interval, -0.6 to 2.2). The rate of loss of chromosomally normal fetuses after chorionic villus sampling was 10.8 percent among women in whom three or four attempts were made to place the transcervical catheter, as compared with 2.9 percent in those in whom only one attempt was necessary (P<0.01). There were no serious maternal infections among the women in this study or among an additional 1990 women who underwent chorionic villus sampling (upper 95 percent confidence limit, 0.08 percent).

We conclude that chorionic villus sampling is a safe and effective technique for the early prenatal diagnosis of cytogenetic abnormalities, but that it probably entails a slightly higher risk of procedure failure and of fetal loss than does amniocentesis. (N Engl J Med 1989; 320: 609–17.)

Funding and Disclosures

Supported by grants (HD-19863, 19866, 19867, 19872, 19881, 19886, 19888, and 19897) from the National Institute of Child Health and Human Development.

We are indebted to our patients for their cooperation and to numerous professional staff members for their substantial contributions; these include Marie Barr and Darcy Novello of Jefferson Medical College; Jane Schuette, Leslie Vought, Richard Berkowitz, and Fred Gilbert of the Mount Sinai School of Medicine; Miriam Di Maio, Angela Scioscia, Joshua Copel, Roy Breg, Nancy Lockwood, Jacqueline Green, and Teresa Yang-Feng of Yale University; Barbara Rosinsky and Alice Martin of Northwestern University; Beth Fine, Lora Baum, and Yury Verlinsky of Michael Reese Hospital and Medical Center; Karen Copeland and Kurt Fenolio of Baylor College of Medicine; Alison Porter, Tim Tomashek, and Steve Schonberg of the University of California at San Francisco; David Fratt and Dina Amin of the George Washington University Biostatistics Center; and George Reed and Diane Wetherill of the National Institute of Child Health and Human Development.

Author Affiliations

From the National Institute of Child Health and Human Development, Bethesda, Md. (G.G.R., F.F. de la C., P.H.S.); Thomas Jefferson University, Philadelphia (L.G.J., R.J.W.); the Biostatistics Center, George Washington University, Washington, D.C. (S.E.S., J.M.Z.); Mount Sinai School of Medicine, New York (R.J.D., L.L.); the University of California at San Francisco (M.S.G., J.D.G.); Baylor College of Medicine, Houston (D.H.L., R.J.C); the University of Miami, Miami (H.A.L.); Yale University, New Haven, Conn. (M.J.M., J.C.H.); Michael Reese Hospital and Medical Center, Chicago (E.P., N.A.G.); and North-western University, Evanston, I11. (J.L.S., S.E.). Address reprint requests to Dr. Rhoads at the Epidemiology Branch, Prevention Research Program, National Institute of Child Health and Human Development, National Institutes of Health, EPN Bldg., Rm. 640, Bethesda, MD 20892.

Print Subscriber? Activate your online access.